FindTrial
Sign In

Ticagrelor versus clopidogrel during percutaneous coronary intervention in high-bleeding-risk patients with acute coronary syndrome

Ticagrelor versus clopidogrel during percutaneous coronary intervention in high-bleeding-risk patients with acute coronary syndrome

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000035165
Enrollment
Unknown
Registered
2020-08-02
Start date
2020-08-04
Completion date
Unknown
Last updated
2020-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary atherosclerotic heart disease

Interventions

Ticagrelor vs. clopidogrel:Nil

Sponsors

The First Affiliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: (1) Patients aged >= 18 years who underwent PCI at the First Affiliated Hospital of Zhengzhou University from January to September 2019. (2) Patients had a high risk of bleeding and acute coronary syndrome. (3) Patients received ticagrelor or clopidogrel for 1 year after PCI.

Exclusion criteria

Exclusion criteria: nil

Design outcomes

Primary

MeasureTime frame
net adverse clinical events;—

Secondary

MeasureTime frame
major adverse cardiovascular events;myocardial infarction;all-cause mortality;stroke;major bleeding;stent thrombosis;urgent target vessel revascularization;—

Countries

China

Contacts

Public ContactKui Chen

The First Affiliated Hospital of Zhengzhou University

fccchenk@zzu.edu.cn+86 13803859349

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 8, 2026